Zoetis Inc.

ZTS Healthcare · Drug Manufacturers - Specialty & Generic
Delayed 15 min
Last close
$73.25
Jun 29, 2026
52-week range
$72.38 — $161.77
-55% from high
Market cap
30.7B
Diluted basis
Dividend yield
279.0%
P/E
12.0
Trailing
Filing.fyi verdict · Jun 29, 2026

Deep value.

Deep Value (Bullish) — Filing.fyi's reading derived from the latest 10-K and forensic scores.

Bullish Beneish: -2.45Altman Z″: 4.49Piotroski: 6/9
RED DEEP 83 / 100
Composite Health
Forensic readings · derived from the latest filing

The four readings.

Each score answers a different question. The composite at the top is the average; the disagreement below is the story.
Beneish M Earnings manipulation
-2.45
Clean
−3.0 threshold −1.78 +1.0
Altman Z″ Bankruptcy proximity
4.49
Safe
0 threshold 1.10 / 2.60 4.0
Piotroski F Fundamental health (0–9)
6
Mixed
0 threshold 6+ 9
AI synthesis · grounded in this ticker's SEC filings · drag to highlight, releases the composer

What the filing actually says.

AI · wry-editorial preset

Zoetis’s latest 10-Q, filed May 7, 2026, presents a narrative that frequently directs the reader elsewhere for context. The Management’s Discussion and Analysis (MD&A) explicitly refers to the 2025 10-K for details on the operating environment, and highlights the use of non-GAAP financial measures—non-standard metrics often adjusted by management—for operational results and adjusted net income. This quarter’s revenue was $2,262 million, an increase from $2,198 million in the prior year period, suggesting continued top-line growth.

Forensic scores paint a picture of financial stability. Beneish’s 1999 eight-ratio earnings-manipulation detector registers at -2.4477, well below the -1.78 threshold that would suggest elevated manipulation risk. Altman’s Z″, a 1968 bankruptcy-distress index, stands at 4.49, firmly in the “safe” category, indicating minimal near-term solvency concerns. The Piotroski F-Score, a 2000 9-point fundamental strength scan, comes in at 6.0, suggesting a generally sound financial position, though not reaching the highest tier of fundamental strength.

The MD&A explicitly notes the Quarterly Variability of Financial Results, attributing it to factors such as tariffs, global macroeconomic conditions, competitive dynamics, and geopolitical tensions. This section, while brief, serves as a reminder that even established companies operate within a complex, unpredictable external environment. The company’s choice to direct readers to its 2025 Annual Report on Form 10-K for a full description of its operating environment means this 10-Q provides updates rather than a comprehensive standalone overview of these material factors.

This filing offers a snapshot of Zoetis’s financial health and reporting practices, indicating robust forensic scores and a structured approach to disclosures. It highlights management’s reliance on non-GAAP metrics and cross-referencing to prior annual reports for foundational context. However, the 10-Q does not, by itself, provide a complete basis for assessing the security’s intrinsic value or future market performance, which would require deeper analysis of sector trends, competitive positioning, and the long-term impact of the macroeconomic factors mentioned.

SEC filings · last 12 months

Filing timeline

View all on EDGAR →
  • May 7, 2026
    10-Q
    Quarterly report (2026-03-31)Period: 2026-03-310
    Read →
  • May 7, 2026
    8-K
    Material event (2026-05-07)### Item 2.02 Results of Operations and Financial Condition On May 7, 2026, Zoetis Inc . (the Company) issued a press release reporting its financial results fo0
    Read →
  • Apr 8, 2026
    DEF 14A
    Proxy statement (2025-12-31)0
    Read →
  • Feb 12, 2026
    10-K
    Annual report (2025-12-31)Period: 2025-12-310
    Read →
  • Feb 12, 2026
    8-K
    Material event (2026-02-12)### Item 2.02 Results of Operations and Financial Condition On February 12, 2026, Zoetis Inc . (the Company) issued a press release announcing its financial res0
    Read →
  • Feb 5, 2026
    8-K
    Material event (2026-02-05)No specific items found in 8-K.0
    Read →
Member feature · Custom Q&A
Ask anything about ZTS's filings.
Plain-English answer, cited from the company's own 10-K and recent 10-Qs. No buy/sell advice.
Ask a question →
Further reading · curated for this filing

If this case caught your eye

Affiliate links — Filing.fyi earns a commission on Amazon purchases. We pick the books first, attach the link second.

Financial Shenanigans

Howard M. Schilit

Schilit's framework for the seven shenanigan types is the standard reference for the kind of MD&A pattern-matching this site does.

View on Amazon →

The Interpretation of Financial Statements

Benjamin Graham

The original — and still the clearest — explanation of why working-capital trends matter more than headline earnings.

View on Amazon →
Quality of Earnings

Quality of Earnings

Thornton L. O'glove

Out of print, expensive, worth it. The chapter on receivables-vs-revenue divergence applies almost word-for-word to most distressed filings.

View on Amazon →